Technological Integration Reshaping the Global Image-guided Biopsy Landscape

[thorat Ketan]

The global Image-guided Biopsy Market Share, valued at USD 4.01 billion in 2023, is projected to reach USD 6.98 billion by 2032, growing at a CAGR of 6.35% during the forecast period of 2024 to 2032, according to the latest industry analysis. This growth is being fueled by rapid technological advancements in diagnostic imaging, a growing global burden of cancer and chronic diseases, and an increasing demand for minimally invasive diagnostic procedures.

Image-guided biopsy represents a crucial advancement in diagnostic medicine, allowing healthcare professionals to obtain tissue samples with high precision using imaging modalities such as ultrasound, MRI, CT, and X-ray. These procedures enable earlier, more accurate diagnoses, reduce complications, and improve treatment planning, especially in oncology.

Get Free Sample Report on Image-guided Biopsy market  

https://www.snsinsider.com/sample-request/2859

Key Drivers of Market Growth

1. Rising Incidence of Cancer and Chronic Diseases

Cancer continues to be one of the leading causes of mortality worldwide. According to the World Health Organization (WHO), there were over 20 million new cancer cases globally in 2023, with this number projected to rise significantly in the coming years. Early and accurate diagnosis is vital in cancer management, and image-guided biopsies offer a less invasive yet highly precise method of detecting malignancies, contributing significantly to improved patient outcomes.

2. Technological Advancements in Imaging Systems

Continual innovations in imaging technologies are expanding the capabilities of biopsy systems. High-resolution imaging, real-time guidance, and fusion imaging are making biopsies safer and more accurate. Companies are investing in AI-powered imaging platforms, portable systems, and software-enhanced guidance systems, enhancing the diagnostic capabilities of clinicians while reducing procedure time.

3. Growing Preference for Minimally Invasive Procedures

Healthcare systems globally are leaning toward less invasive diagnostic and therapeutic techniques to minimize hospital stays, reduce complications, and cut down overall healthcare costs. Image-guided biopsies perfectly align with this trend, making them increasingly popular across diagnostic centers and hospitals.

4. Expanding Geriatric Population

With aging populations more susceptible to chronic diseases, the demand for advanced diagnostic solutions is expected to increase. Older adults often present complex health profiles, necessitating safe and precise diagnostic methods like image-guided biopsies to avoid unnecessary surgical interventions.

KEY MARKET SEGMENTATION

By Process:

• Vacuum Assisted Biopsy
• Core Needle
• Fine Needle

By Image Guided Technology:

• MRI
• Ultrasound
• Mammography
• CT
• X-Ray

By End User:

• Hospitals And Clinics
• Ambulatory Surgical Centers
• Research and Academic Institutes

 

Key Players

• Ethicon Endo-Surgery: (ENDOPOUCH Retrieval Pouch, ENDOLOOP Ligature)
• Intact Medical Corporation: (Intact Breast Lesion Excision System, Intact Excise)
• Galini SRL: (Galini Biopsy Needle, Galini Coaxial Needle)
• Hologic Inc.: (Brevera Breast Biopsy System, Eviva Breast Biopsy System)
• Leica Biosystems Nussloch GmbH: (Mammotome Elite Biopsy System, Mammotome Revolve Biopsy System)
• R. Bard, Inc.: (Mission Biopsy Instrument, Vacora Biopsy System)
• Becton, Dickinson and Company: (BD Vacutainer Biopsy Needle, BD Temno Biopsy Device)
• Argon Medical Devices: (SuperCore Biopsy Instrument, Tru-Core II Biopsy Needle)
• Cook Medical Incorporated: Quick-Core Biopsy Needle, EchoTip ProCore Endobronchial Ultrasound Needle)
• Encapsule Medical Devices LLC(Encapsule Biopsy System, Encapsule Core Biopsy Needle)
• Siemens Healthineers: (ACUSON S2000 Ultrasound System, Mammomat Inspiration Biopsy Unit)
• Philips Healthcare: Affiniti 70 Ultrasound System, MicroDose SI Mammography System)
• GE Healthcare: (Invenia ABUS, Senographe Pristina)
• Canon Medical Systems(Aplio i-series Ultrasound, Celesteion PET/CT System)
• Fujifilm Holdings Corporation(ARIETTA 850 Ultrasound, ASPIRE Cristalle Mammography System)
• Carestream Health: (DRX-Ascend System, DRX-Revolution Mobile X-ray System)
• Hitachi Medical Systems: (ARIETTA 70 Ultrasound, Supria CT Scanner)

 

Recent Developments

• October 2024: Philips Healthcare announced the launch of its next-generation ultrasound-guided biopsy platform equipped with AI-based lesion targeting, improving diagnostic accuracy in breast and prostate biopsies.
• March 2024: BD launched a new disposable biopsy needle designed for MRI compatibility, enhancing the precision of soft-tissue biopsies with reduced procedural risk.
• June 2023: Siemens Healthineers introduced a hybrid CT-guided biopsy solution tailored for oncology centers, integrating radiation dose reduction technology with real-time imaging.

Challenges and Opportunities

Despite strong growth prospects, the market faces some challenges including:

• High costs of imaging systems and biopsy procedures, especially in low- and middle-income countries.
• Shortage of trained professionals capable of operating advanced imaging devices.
• Regulatory hurdles associated with device approval and integration with hospital systems.

However, these challenges are being offset by promising trends:

• Artificial Intelligence (AI) and Machine Learning (ML): Integration of AI in imaging is enabling faster and more accurate lesion detection and biopsy guidance.
• Telemedicine and Remote Diagnostics: Post-pandemic trends are encouraging remote access to diagnostics, paving the way for portable and cloud-integrated biopsy systems.
• Public Awareness Campaigns: Governments and non-profits are increasingly promoting early detection and screening for cancers like breast and prostate, driving higher procedural volumes.

Future Outlook

The image-guided biopsy market is on a strong growth path, anchored by rising disease prevalence, shifting clinical preferences, and a global emphasis on early, accurate diagnosis. As innovation continues to transform healthcare, image-guided biopsies will become central to precision diagnostics, offering significant benefits in oncology, chronic disease management, and even infectious disease detection.

With market revenues expected to rise from USD 4.01 billion in 2023 to USD 6.98 billion by 2032, stakeholders across the healthcare ecosystem—including technology developers, hospitals, and policy makers—must prioritize the adoption and accessibility of these advanced diagnostic solutions.

 About US

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

Contact Us:

Jagney Dave - Vice President of Client Engagement

Phone: [phone] (US) | [phone] (UK)